Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Lung Cancer Clinical Trial

Official title:

Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01766739
• Other study ID #: 12-169
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: January 2013
• Est. completion date: January 2025

Study information

• Verified date: February 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety of the GL-ONC1 vaccinia virus at different dose levels. The investigators want to find out what effects, good and/or bad, it has on the patient and the malignant pleural effusion. A malignant pleural effusion is a build up of fluid in the chest cavity cause by the cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 18
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of histologically or cytologically documented, malignant pleural effusions (primary non-small-cell lung carcinoma, mesothelioma, and other histologies), who have free pleural space (partial or total) that permits the intrapleural drug instillation. This includes cytologically negative pleural effusion in conjunction with histologically proven malignancy involving the pleura.

• Age must be = 18 years.

• All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0) Grade = 1.

• Any surgery, where general anesthesia was administered, must have occurred at least 14 days prior to study enrollment.

• Chemotherapy, radiotherapy or immunotherapy must have stopped more than 7 days prior to receiving study drug; however, small field palliative radiotherapy, TKI therapies and hormonal therapies are allowed.

• Patients with stage IV malignancy (non-mesothelioma) must have had a brain scan (MRI or CT with contrast) showing no evidence of disease progression within 8 weeks of study enrollment.

• ECOG Zubrod = 2.

• Required baseline laboratory data include:

• Absolute neutrophil count (ANC) = 1.5 × 109 [SI units 10^9/L],

• Platelets = 100 ×10^9 [SI units 10^9/L],

• Hemoglobin = 9.0 g/dL [SI units gm/L],

• Serum creatinine = 1.5 × upper limit of normal (ULN),

• Bilirubin = 1.5 × ULN,

• AST/ALT = 2.5 × ULN (= 5 × ULN in the presence of liver metastases)

• Negative pregnancy test for females of childbearing potential.

Exclusion Criteria:

• Pregnant or breast-feeding women.

• Patients with fever or any active systemic infections, including known HIV, hepatitis B or C.

• Patients on immunosuppressive therapy or with immune system disorders, including autoimmune diseases.

• Concurrent steroid use of more than an equivalent of 20 mg/day prednisone (or equivalent).

• Prior splenectomy.

• Previous organ transplant.

• Patients with clinically significant dermatological disorders, e.g., eczema or psoriasis, as judged by the principal investigator, or any unhealed skin wounds or ulcers.

• Clinically significant cardiac disease (New York Heart Association, Class III or IV).

• Dementia or altered mental status that would prohibit informed consent.

• Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality, that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results and, in the judgment of the principal investigator, would make the patient inappropriate for this study.

• Known allergy to ovalbumin or other egg products.

• Prior gene therapy treatments or prior therapy with cytolytic virus of any type.

• Concurrent therapy with any other investigational anticancer agent.

• Concurrent antiviral agent active against vaccinia virus (e.g. cidofovir, vaccinia immunoglobulin) during the study.

Related Conditions & MeSH terms

• Lung Cancer
• Mesothelioma
• Pleural Effusion
• Pleural Effusion, Malignant
• Vaccinia

Intervention

Biological:
• GL-ONC1
Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Genelux Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD)	MTD is to provide a dosing recommendation for subsequent Phase II studies. Three patients will be enrolled in each cohort at the dose levels shown in the table below in order to determine the Maximum Tolerated Dose (MTD). At the beginning of a new dose level, only one patient will be treated. The first patient in each cohort must be treated and complete 14 days of post-treatment evaluation prior to the treatment of the remaining two patients in that cohort.	2 years
Secondary	safety	The safety, tolerability and feasibility of GL-ONC1 will be assessed by the evaluation of the type, frequency, and severity of adverse events (AEs), changes in clinical laboratory tests (hematological and chemistry), immunogenicity and physical examination. All AEs and laboratory toxicities will be graded on the CTCAE (version 4).	2 years
Secondary	detection of virus in body fluids	Patients will undergo serial sampling of blood, sputum, urine samples and pleural drainage for evaluation of viral particles by VPA immediately before treatment, and on days 2, 3, 4 and 5 pretreatment.	days 2, 3, 4, & 5. pretreatment
Secondary	evaluation of viral appearance in tumor	Unless medically contraindicated, patients will undergo Video-Assisted Thoracic Surgery (VATS) with pleural biopsies to assess for green fluorescent protein (GFP) viral expression in tumor and surrounding tissues, and if appropriate, to perform pleurodesis at 2-7 days after intrapleural instillation of virus. Random pleural biopsies and GFP-directed biopsies will be performed to allow for assessment of viral presence. Viral plaque assays (VPA) will be performed in tumor biopsies. Immunohistochemical (IHC) and beta-glucuronidase assay staining for GL-ONC1 will be performed on both GFP (-) and (+) areas at videothoracoscopy (if applicable).	2-9 days after intrapleural instillation of virus
Secondary	Therapeutic efficacy	Therapeutic efficacy will be investigated with CT scans pretreatment and at Day 60 (+/-10) posttreatment. Response by RECIST criteria (and by modified RECIST - for mesothelioma tumors) will be summarized for each dose level using descriptive statistics.	day 60 post treatment (+/-10 days)

External Links

•   Memorial Sloan Kettering Cancer Center